Novartis AG is planning to evaluate its investigational oral spinal muscular atrophy (SMA) drug branaplam as a treatment for Huntington's disease (HD), suggesting that the future prospects for the therapy may be best served by focusing on this other devastating inherited neurodegenerative condition instead.
Novartis Takes Huntington's Path With SMA Therapy Branaplam
Priority Has Shifted After Rival Roche's Success
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
